Literature DB >> 6438678

Cerebromicrocirculatory defects in animal model of depression.

S H Preskorn, T A Kent, R K Glotzbach, G H Irwin, J V Solnick.   

Abstract

In the tetrabenazine (TBZ) model of depression, the cerebromicrocirculation was discovered to respond abnormally to metabolic demand as mimicked by the administration of CO2. Altered responsivity of cerebral blood flow and effective permeability of the blood--brain barrier to changes in PaCO2 were found. These physiologic defects coincided temporally with TBZ-induced depletion of central norepinephrine and dopamine and with the development of the behavioral effects of TBZ (the end points used to test the antidepressant potential of experimental drugs). Pretreatment with amitriptyline (a standard antidepressant and amine reuptake inhibitor) prevented the development of these TBZ-induced abnormalities in the cerebromicrocirculation, just as it prevented the behavioral effects.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6438678     DOI: 10.1007/bf00427445

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  13 in total

1.  Abnormality of the blood-cerebrospinal fluid barrier of patients suffering from a depressive illness.

Authors:  A J COPPEN
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-05       Impact factor: 10.154

2.  Central noradrenergic regulation of cerebral blood flow and vascular permeability.

Authors:  M E Raichle; B K Hartman; J O Eichling; L G Sharpe
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

Review 3.  Central adrenergic regulation of cerebral microvascular permeability and blood flow: pharmacologic evidence.

Authors:  S H Preskorn; B K Hartman; M E Raichle; L W Swanson; H B Clark
Journal:  Adv Exp Med Biol       Date:  1980       Impact factor: 2.622

4.  Cerebral blood flow in depression.

Authors:  R J Mathew; J S Meyer; D J Francis; K M Semchuk; K Mortel; J L Claghorn
Journal:  Am J Psychiatry       Date:  1980-11       Impact factor: 18.112

5.  Medical therapies for mood disorders alter the blood-brain barrier.

Authors:  S H Preskorn; G H Irwin; S Simpson; D Friesen; J Rinne; G Jerkovich
Journal:  Science       Date:  1981-07-24       Impact factor: 47.728

6.  Hypercapnia and hypoxia: chemoreceptor-mediated control of locus coeruleus neurons and splanchnic, sympathetic nerves.

Authors:  M Elam; T Yao; P Thorén; T H Svensson
Journal:  Brain Res       Date:  1981-10-19       Impact factor: 3.252

7.  A dual label radiotracer technique for the simultaneous measurement of cerebral blood flow and the single-transit cerebral extraction of diffusion-limited compounds in rats.

Authors:  G H Irwin; S H Preskorn
Journal:  Brain Res       Date:  1982-10-07       Impact factor: 3.252

8.  Role of the central adrenergic system in mediating amitriptyline-induced alteration in the mammalian blood-brain barrier in vivo.

Authors:  S H Preskorn; B K Hartman; G H Irwin; C W Hughes
Journal:  J Pharmacol Exp Ther       Date:  1982-11       Impact factor: 4.030

9.  Brain concentrations of tricyclic antidepressants: single-dose kinetics and relationship to plasma concentrations in chronically dosed rats.

Authors:  R K Glotzbach; S H Preskorn
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

10.  The use of dopamine -hydroxylase as a marker for the central noradrenergic nervous system in rat brain.

Authors:  B K Hartman; D Zide; S Udenfriend
Journal:  Proc Natl Acad Sci U S A       Date:  1972-09       Impact factor: 11.205

View more
  4 in total

1.  The VMAT-2 inhibitor tetrabenazine alters effort-related decision making as measured by the T-maze barrier choice task: reversal with the adenosine A2A antagonist MSX-3 and the catecholamine uptake blocker bupropion.

Authors:  Samantha E Yohn; Christian Thompson; Patrick A Randall; Christie A Lee; Christa E Müller; Younis Baqi; Mercè Correa; John D Salamone
Journal:  Psychopharmacology (Berl)       Date:  2014-10-17       Impact factor: 4.530

Review 2.  Activational and effort-related aspects of motivation: neural mechanisms and implications for psychopathology.

Authors:  John D Salamone; Samantha E Yohn; Laura López-Cruz; Noemí San Miguel; Mercè Correa
Journal:  Brain       Date:  2016-05       Impact factor: 13.501

3.  Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine: implications for animal models of the motivational symptoms of depression.

Authors:  Eric J Nunes; Patrick A Randall; Evan E Hart; Charlotte Freeland; Samantha E Yohn; Younis Baqi; Christa E Müller; Laura López-Cruz; Mercè Correa; John D Salamone
Journal:  J Neurosci       Date:  2013-12-04       Impact factor: 6.167

4.  The VMAT-2 inhibitor tetrabenazine affects effort-related decision making in a progressive ratio/chow feeding choice task: reversal with antidepressant drugs.

Authors:  Patrick A Randall; Christie A Lee; Eric J Nunes; Samantha E Yohn; Victoria Nowak; Bilal Khan; Priya Shah; Saagar Pandit; V Kiran Vemuri; Alex Makriyannis; Younis Baqi; Christa E Müller; Merce Correa; John D Salamone
Journal:  PLoS One       Date:  2014-06-17       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.